according to GB/T 16483 and GB/T 17519



Oxytetracycline / Diclofenac Formulation

Version Revision Date: SDS Number: Date of last issue: 2025/04/14 7.1 2025/05/20 4156023-00020 Date of first issue: 2019/04/17

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Oxytetracycline / Diclofenac Formulation

Manufacturer or supplier's details

Company : MSD

Address : No. 485 Jing Tai Road

Pu Tuo District - Shanghai - China 200331

Telephone : +1-908-740-4000

Emergency telephone number : 86-571-87268110

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

Emergency Overview

Appearance : liquid

Colour : brown, Greenish yellow

Odour : characteristic

Causes mild skin irritation. May cause an allergic skin reaction. Causes serious eye irritation. May damage fertility. May damage the unborn child. May cause damage to organs through prolonged or repeated exposure. Very toxic to aquatic life with long lasting effects.

GHS Classification

Skin corrosion/irritation : Category 3

Serious eye damage/eye irri- :

tation

Category 2A

Skin sensitisation : Category 1

Reproductive toxicity : Category 1A

Specific target organ toxicity - :

repeated exposure

Category 2

Short-term (acute) aquatic

hazard

Category 1

according to GB/T 16483 and GB/T 17519



Oxytetracycline / Diclofenac Formulation

Version Revision Date: SDS Number: Date of last issue: 2025/04/14 7.1 2025/05/20 4156023-00020 Date of first issue: 2019/04/17

Long-term (chronic) aquatic

hazard

Category 1

GHS label elements

Hazard pictograms







Signal word : Danger

Hazard statements : H316 Causes mild skin irritation.

H317 May cause an allergic skin reaction.

H319 Causes serious eye irritation.

H360FD May damage fertility. May damage the unborn child. H373 May cause damage to organs through prolonged or re-

peated exposure.

H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements

Prevention:

P203 Obtain, read and follow all safety instructions before use.

P260 Do not breathe mist or vapours.

P264 Wash skin thoroughly after handling.

P272 Contaminated work clothing should not be allowed out of the workplace.

nie workpiace.

P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection/ hearing protection.

Response:

P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

P318 IF exposed or concerned, get medical advice.

P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention.

P333 + P317 If skin irritation or rash occurs: Get medical help.

P337 + P317 If eye irritation persists: Get medical help.

P362 + P364 Take off contaminated clothing and wash it before

reuse.

P391 Collect spillage.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

according to GB/T 16483 and GB/T 17519



Oxytetracycline / Diclofenac Formulation

Version Revision Date: SDS Number: Date of last issue: 2025/04/14 7.1 2025/05/20 4156023-00020 Date of first issue: 2019/04/17

Physical and chemical hazards

Not classified based on available information.

Health hazards

Causes mild skin irritation. Causes serious eye irritation. May cause an allergic skin reaction. May damage fertility. May damage the unborn child. May cause damage to organs through prolonged or repeated exposure.

Environmental hazards

Very toxic to aquatic life. Very toxic to aquatic life with long lasting effects.

Other hazards which do not result in classification

None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
2-Pyrrolidone	616-45-5	>= 50 -< 70
oxytetracycline	79-57-2	>= 20 -< 25
Magnesium oxide	1309-48-4	>= 1 -< 10
Sodium [2-[(2,6-	15307-79-6	>= 1 -< 2.5
dichlorophenyl)amino]phenyl]acetate		
Sodium hydroxymethanesulphinate	6035-47-8	>= 0.1 -< 1

4. FIRST AID MEASURES

General advice In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact In case of contact, immediately flush skin with plenty of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact In case of contact, immediately flush eyes with plenty of water

for at least 15 minutes.

If easy to do, remove contact lens, if worn.

Get medical attention.

If swallowed If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Most important symptoms

Causes mild skin irritation.

and effects, both acute and May cause an allergic skin reaction. delayed

Causes serious eve irritation.

May damage fertility. May damage the unborn child.

according to GB/T 16483 and GB/T 17519



Oxytetracycline / Diclofenac Formulation

Version Revision Date: SDS Number: Date of last issue: 2025/04/14 7.1 2025/05/20 4156023-00020 Date of first issue: 2019/04/17

May cause damage to organs through prolonged or repeated

exposure.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire-

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

Chlorine compounds Nitrogen oxides (NOx)

Sodium oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- :

tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

barriers)

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for : Soak up with inert absorbent material.

according to GB/T 16483 and GB/T 17519



Oxytetracycline / Diclofenac Formulation

Version Revision Date: SDS Number: Date of last issue: 2025/04/14 7.1 2025/05/20 4156023-00020 Date of first issue: 2019/04/17

containment and cleaning up For large spills, provide dyking or other appropriate contain-

ment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

7. HANDLING AND STORAGE

Handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe mist or vapours.

Do not swallow. Do not get in eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Avoidance of contact : Oxidizing agents

Storage

Conditions for safe storage : Keep in properly labelled containers.

Store locked up. Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Packaging material : Unsuitable material: None known.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
--------------------	-------------------------------------	--	-------

according to GB/T 16483 and GB/T 17519



Oxytetracycline / Diclofenac Formulation

Version Revision Date: SDS Number: Date of last issue: 2025/04/14 7.1 2025/05/20 4156023-00020 Date of first issue: 2019/04/17

oxytetracycline	79-57-2	TWA	500 μg/m3 (OEB 2)	Internal		
	Further inform	Further information: DSEN				
		Wipe limit	100 μg/100 cm ²	Internal		
Magnesium oxide	1309-48-4	PC-TWA (Fumes)	10 mg/m3	CN OEL		
		TWA (Inhal- able particu- late matter)	10 mg/m3	ACGIH		
Sodium [2-[(2,6-dichloro-phenyl)amino]phenyl]acetate	15307-79-6	TWA	60 μg/m3 (OEB 3)	Internal		
	Further information: Skin					
		Wipe limit	6000 µg/100cm2	Internal		

Engineering measures : Use appropriate engineering controls and manufacturing

technologies to control airborne concentrations (e.g., drip-

less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face con-

tainment devices). Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type : Combined particulates and organic vapour type Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis-

posable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Hygiene measures : If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the work-

according to GB/T 16483 and GB/T 17519



Oxytetracycline / Diclofenac Formulation

Version Revision Date: SDS Number: Date of last issue: 2025/04/14 7.1 2025/05/20 4156023-00020 Date of first issue: 2019/04/17

ing place.

When using do not eat, drink or smoke.

Contaminated work clothing should not be allowed out of the

workplace.

Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : liquid

Colour : brown, Greenish yellow

Odour : characteristic

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : -33 °C

Initial boiling point and boiling

range

100.5 °C

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower :

flammability limit

No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : 1.15 - 1.19 (25 °C)

Density : No data available

Solubility(ies)

Water solubility : soluble

according to GB/T 16483 and GB/T 17519



Oxytetracycline / Diclofenac Formulation

Version Revision Date: SDS Number: Date of last issue: 2025/04/14 7.1 2025/05/20 4156023-00020 Date of first issue: 2019/04/17

Partition coefficient: n-

octanol/water

: Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, dynamic : 50.3 - 50.7 mPa.s (25 °C)

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : Not applicable

10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

: Can react with strong oxidizing agents.

Conditions to avoid : None known. Incompatible materials : Oxidizing agents

Hazardous decomposition : No hazardous decomposition products are known.

products

11. TOXICOLOGICAL INFORMATION

Exposure routes : Inhalation

Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg

Method: Calculation method

Components:

2-Pyrrolidone:

according to GB/T 16483 and GB/T 17519



Oxytetracycline / Diclofenac Formulation

Version Revision Date: SDS Number: Date of last issue: 2025/04/14 7.1 2025/05/20 4156023-00020 Date of first issue: 2019/04/17

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 401

Assessment: The substance or mixture has no acute oral tox-

icity

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Method: OECD Test Guideline 402

Assessment: The substance or mixture has no acute dermal

toxicity

oxytetracycline:

Acute oral toxicity : LD50 (Rat): 4,800 mg/kg

LD50 (Mouse): 2,240 mg/kg

Remarks: Evidence of phototoxicity was observed

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of :

administration)

LD50 (Rat): 4,840 mg/kg

Application Route: Intramuscular

LD50 (Mouse): 3,500 mg/kg Application Route: Subcutaneous

Magnesium oxide:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 423

Assessment: The substance or mixture has no acute oral tox-

icitv

Remarks: Based on data from similar materials

Acute inhalation toxicity : LC50 (Rat): > 2.1 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Method: OECD Test Guideline 403

Remarks: Based on data from similar materials

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Acute oral toxicity : LD50 (Rat): 55 - 240 mg/kg

LD50 (Mouse): 170 - 389 mg/kg

Acute toxicity (other routes of :

administration)

LD50 (Rat): 97 - 161 mg/kg

Application Route: Intravenous

LD50 (Mouse): 92 - 147 mg/kg Application Route: Intravenous

according to GB/T 16483 and GB/T 17519



Oxytetracycline / Diclofenac Formulation

Version Revision Date: SDS Number: Date of last issue: 2025/04/14 7.1 2025/05/20 4156023-00020 Date of first issue: 2019/04/17

Sodium hydroxymethanesulphinate:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Method: OECD Test Guideline 423

Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 402

Remarks: Based on data from similar materials

Skin corrosion/irritation

Causes mild skin irritation.

Components:

2-Pyrrolidone:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

oxytetracycline:

Remarks : No data available

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Result : irritating

Sodium hydroxymethanesulphinate:

Species : Rat

Result : No skin irritation

Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:

2-Pyrrolidone:

Result : Irritation to eyes, reversing within 21 days Remarks : Based on national or regional regulation.

oxytetracycline:

Remarks : No data available

Magnesium oxide:

Species : Rabbit

Result : No eye irritation

according to GB/T 16483 and GB/T 17519



Oxytetracycline / Diclofenac Formulation

Version Revision Date: SDS Number: Date of last issue: 2025/04/14 7.1 2025/05/20 4156023-00020 Date of first issue: 2019/04/17

Method : OECD Test Guideline 405

Remarks : Based on data from similar materials

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Result : Mild eye irritation

Sodium hydroxymethanesulphinate:

Species : Rabbit

Result : No eye irritation

Method : OECD Test Guideline 405

Remarks : Based on data from similar materials

Respiratory or skin sensitisation

Skin sensitisation

May cause an allergic skin reaction.

Respiratory sensitisation

Not classified based on available information.

Components:

2-Pyrrolidone:

Test Type : Local lymph node assay (LLNA)

Exposure routes : Skin contact Species : Mouse

Method : OECD Test Guideline 429

Result : negative

Remarks : Based on data from similar materials

oxytetracycline:

Test Type : Human repeat insult patch test (HRIPT)

Result : Sensitiser

Magnesium oxide:

Test Type : Maximisation Test Exposure routes : Skin contact Species : Guinea pig

Method : OECD Test Guideline 406

Result : negative

Remarks : Based on data from similar materials

Sodium hydroxymethanesulphinate:

Test Type : Maximisation Test Exposure routes : Skin contact Species : Guinea pig

Method : OECD Test Guideline 406

Result : negative

according to GB/T 16483 and GB/T 17519



Oxytetracycline / Diclofenac Formulation

Version Revision Date: SDS Number: Date of last issue: 2025/04/14 7.1 2025/05/20 4156023-00020 Date of first issue: 2019/04/17

Remarks : Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

Components:

2-Pyrrolidone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Method: OECD Test Guideline 476

Result: negative

Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intraperitoneal injection

Method: OECD Test Guideline 474

Result: negative

oxytetracycline:

Genotoxicity in vitro : Test Type: Microbial mutagenesis assay (Ames test)

Result: negative

Test Type: Mouse Lymphoma

Metabolic activation: Metabolic activation

Result: positive

Test Type: sister chromatid exchange assay Test system: Chinese hamster ovary cells

Result: equivocal

Test Type: Chromosomal aberration

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse

Cell type: Bone marrow Application Route: Oral Result: equivocal

Test Type: in vivo assay

Species: Mouse

according to GB/T 16483 and GB/T 17519



Oxytetracycline / Diclofenac Formulation

Version Revision Date: SDS Number: Date of last issue: 2025/04/14 7.1 2025/05/20 4156023-00020 Date of first issue: 2019/04/17

Application Route: Intraperitoneal injection

Result: negative

Germ cell mutagenicity -

Assessment

Weight of evidence does not support classification as a germ

cell mutagen.

Magnesium oxide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Method: OECD Test Guideline 471

Result: negative

Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

Remarks: Based on data from similar materials

Test Type: In vitro mammalian cell gene mutation test

Method: OECD Test Guideline 476

Result: negative

Remarks: Based on data from similar materials

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Mouse Lymphoma

Result: negative

Genotoxicity in vivo : Test Type: Chromosomal aberration

Species: CHO Result: negative

Sodium hydroxymethanesulphinate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Method: OECD Test Guideline 471

Result: negative

Remarks: Based on data from similar materials

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intraperitoneal injection Method: OECD Test Guideline 474

Result: positive

Remarks: Based on data from similar materials

Germ cell mutagenicity -

Assessment

Positive result(s) from in vivo mammalian somatic cell muta-

genicity tests.

according to GB/T 16483 and GB/T 17519



Oxytetracycline / Diclofenac Formulation

Version Revision Date: SDS Number: Date of last issue: 2025/04/14 7.1 2025/05/20 4156023-00020 Date of first issue: 2019/04/17

Carcinogenicity

Not classified based on available information.

Components:

2-Pyrrolidone:

Species : Mouse
Application Route : Ingestion
Exposure time : 18 month(s)
Result : negative

Remarks : Based on data from similar materials

oxytetracycline:

Species : Mouse
Application Route : Oral
Exposure time : 104 weeks
Result : negative

Species : Rat
Application Route : Oral
Exposure time : 103 weeks
Result : equivocal

Target Organs : Adrenal gland, Pituitary gland

Remarks : The mechanism or mode of action may not be relevant in hu-

mans.

Carcinogenicity - Assess-

ment

Weight of evidence does not support classification as a car-

cinogen

Magnesium oxide:

Species : Mouse
Application Route : Ingestion
Exposure time : 96 weeks
Result : negative

Remarks : Based on data from similar materials

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Species : Rat
Application Route : Oral
Exposure time : 2 Years
Result : negative

Species : Mouse
Application Route : Oral
Exposure time : 2 Years
Result : negative

according to GB/T 16483 and GB/T 17519



Oxytetracycline / Diclofenac Formulation

Version Revision Date: SDS Number: Date of last issue: 2025/04/14 7.1 2025/05/20 4156023-00020 Date of first issue: 2019/04/17

Reproductive toxicity

May damage fertility. May damage the unborn child.

Components:

2-Pyrrolidone:

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: positive

Remarks: Based on data from similar materials

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Ingestion

Result: positive

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse

effects on development, based on animal experiments.

oxytetracycline:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Oral

Fertility: NOAEL: 18 mg/kg body weight

Result: No effects on fertility, No effect on reproduction capac-

ity, No significant adverse effects were reported

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

Embryo-foetal toxicity: LOAEL: 48 mg/kg body weight Result: Postimplantation loss., Skeletal malformations

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

General Toxicity Maternal: LOAEL: 1,200 mg/kg body weight Embryo-foetal toxicity: NOAEL: 1,500 mg/kg body weight

Result: No teratogenic effects

Remarks: Maternal toxicity observed.

Test Type: Embryo-foetal development

Species: Mouse Application Route: Oral

General Toxicity Maternal: LOAEL: 1,325 mg/kg body weight Embryo-foetal toxicity: NOAEL: 2,100 mg/kg body weight

Result: No teratogenic effects

Remarks: Maternal toxicity observed.

according to GB/T 16483 and GB/T 17519



Oxytetracycline / Diclofenac Formulation

Version Revision Date: SDS Number: Date of last issue: 2025/04/14 7.1 2025/05/20 4156023-00020 Date of first issue: 2019/04/17

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Intramuscular

Embryo-foetal toxicity: LOAEL: 41.5 mg/kg body weight Result: Postimplantation loss., No foetal abnormalities

Test Type: Embryo-foetal development

Species: Dog

Application Route: Intramuscular

Embryo-foetal toxicity: LOAEL: 20.75 mg/kg body weight Result: Skeletal and visceral variations, Postimplantation loss.

Reproductive toxicity - As-

sessment

Positive evidence of adverse effects on development from

human epidemiological studies.

Magnesium oxide:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the

reproduction/developmental toxicity screening test

Species: Rat

Application Route: Ingestion

Method: OECD Test Guideline 422

Result: negative

Remarks: Based on data from similar materials

Effects on foetal develop-

ment

Test Type: Combined repeated dose toxicity study with the

reproduction/developmental toxicity screening test

Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 422

Result: negative

Remarks: Based on data from similar materials

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Effects on fertility : Test Type: Fertility

Species: Rat, male and female

Application Route: Oral

Fertility: NOAEL: 4 mg/kg body weight

Result: No effects on fertility

Effects on foetal develop-

ment

Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 1 mg/kg body weight Result: Embryo-foetal toxicity, No teratogenic effects

Test Type: Development

Species: Rabbit Application Route: Oral

Developmental Toxicity: LOAEL: 5 mg/kg body weight Result: Embryo-foetal toxicity, No teratogenic effects

according to GB/T 16483 and GB/T 17519



Oxytetracycline / Diclofenac Formulation

Version Revision Date: SDS Number: Date of last issue: 2025/04/14 7.1 2025/05/20 4156023-00020 Date of first issue: 2019/04/17

Reproductive toxicity - As-

sessment

Suspected of damaging the unborn child.

Sodium hydroxymethanesulphinate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the

reproduction/developmental toxicity screening test

Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 422

Result: negative

Remarks: Based on data from similar materials

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 414

Result: positive

Remarks: Based on data from similar materials

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Components:

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Target Organs : Gastrointestinal tract, Blood, lymphatic system, Liver, Prostate Assessment : Causes damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

2-Pyrrolidone:

Species : Rat

NOAEL : 207 mg/kg Application Route : Ingestion Exposure time : 3 Months

Method : OECD Test Guideline 408

oxytetracycline:

Species : Rat

LOAEL : 198 mg/kg

according to GB/T 16483 and GB/T 17519



Oxytetracycline / Diclofenac Formulation

Version Revision Date: SDS Number: Date of last issue: 2025/04/14 7.1 2025/05/20 4156023-00020 Date of first issue: 2019/04/17

Application Route : Oral
Exposure time : 13 Weeks
Target Organs : Bone

Remarks : No significant adverse effects were reported

Species : Mouse
LOAEL : 7,990 mg/kg
Application Route : Oral
Exposure time : 13 Weeks
Target Organs : Bone

Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : 125 mg/kg
LOAEL : 250 mg/kg
Application Route : Oral
Exposure time : 12 Months
Target Organs : Testis

Remarks : Significant toxicity observed in testing

Species : Rat

NOAEL : 40 mg/kg

LOAEL : 100 mg/kg

Application Route : Intraperitoneal

Exposure time : 14 Days

Target Organs : Kidney

Magnesium oxide:

Species : Rat

NOAEL : >= 1,000 mg/kg
Application Route : Ingestion
Exposure time : 28 Days

Method : OECD Test Guideline 407

Remarks : Based on data from similar materials

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Species : Rat

LOAEL : 0.25 mg/kg Application Route : Oral

Exposure time : 98 w

Target Organs : Gastrointestinal tract, Blood, lymphatic system, Liver, Prostate

Species : Dog
LOAEL : 1 mg/kg
Application Route : Oral
Exposure time : 12 w
Target Organs : Blood

Species : Baboon NOAEL : 0.5 mg/kg

according to GB/T 16483 and GB/T 17519



Oxytetracycline / Diclofenac Formulation

Version Revision Date: SDS Number: Date of last issue: 2025/04/14 7.1 2025/05/20 4156023-00020 Date of first issue: 2019/04/17

LOAEL : 5 mg/kg
Application Route : Oral
Exposure time : 52 w

Target Organs : Gastrointestinal tract, Blood Symptoms : constipation, Diarrhoea

Sodium hydroxymethanesulphinate:

Species : Rat

NOAEL : 600 mg/kg Application Route : Ingestion Exposure time : 90 Days

Method : OECD Test Guideline 408

Remarks : Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

oxytetracycline:

Ingestion : Symptoms: Gastrointestinal disturbance, tooth discoloration

Remarks: May cause birth defects.

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Ingestion : Symptoms: Abdominal pain, Diarrhoea, constipation, heart-

burn, Ulceration, Dizziness, Headache, Breathing difficulties,

Rash

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

2-Pyrrolidone:

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 4,600 - 10,000 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 500 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

: ErC50 (Desmodesmus subspicatus (green algae)): > 500 mg/l

Exposure time: 72 h

EC10 (Desmodesmus subspicatus (green algae)): 22.2 mg/l

Exposure time: 72 h

Toxicity to microorganisms : EC50: > 1,000 mg/l

according to GB/T 16483 and GB/T 17519



Oxytetracycline / Diclofenac Formulation

Version Revision Date: SDS Number: Date of last issue: 2025/04/14 7.1 2025/05/20 4156023-00020 Date of first issue: 2019/04/17

Exposure time: 30 min

Method: OECD Test Guideline 209

oxytetracycline:

Toxicity to fish LC50 (Oryzias latipes (Japanese medaka)): 110 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 621 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

EC50 (Moina macrocopa (Water flea)): 126.7 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Anabaena): 0.032 mg/l

Exposure time: 72 h

NOEC (Anabaena): 0.0031 mg/l

Exposure time: 72 h

M-Factor (Acute aquatic tox-

icity)

10

10

M-Factor (Chronic aquatic

Toxicity to microorganisms

toxicity)

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

EC50 (activated sludge): 17.9 mg/l

NOEC (activated sludge): 0.2 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Magnesium oxide:

LL50 (Pimephales promelas (fathead minnow)): > 100 mg/l Toxicity to fish

Exposure time: 96 h

Remarks: Based on data from similar materials

Toxicity to daphnia and other :

aquatic invertebrates

EL50 (Daphnia magna (Water flea)): > 100 mg/l

Exposure time: 48 h

Remarks: Based on data from similar materials

Toxicity to algae/aguatic

plants

EL50 (Pseudokirchneriella subcapitata (green algae)): > 100

mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

according to GB/T 16483 and GB/T 17519



Oxytetracycline / Diclofenac Formulation

Version Revision Date: SDS Number: Date of last issue: 2025/04/14 7.1 2025/05/20 4156023-00020 Date of first issue: 2019/04/17

Remarks: Based on data from similar materials

Toxicity to microorganisms : EC50: > 100 mg/l

Exposure time: 3 h

Method: OECD Test Guideline 209

Remarks: Based on data from similar materials

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 166.6 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 80.1 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): 71.9

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 49.2

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 0.32 mg/l

Exposure time: 32 d

Method: OECD Test Guideline 210

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 10 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Sodium hydroxymethanesulphinate:

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 10,000 mg/l

Exposure time: 96 h

Remarks: Based on data from similar materials

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 100 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: Based on data from similar materials

Toxicity to algae/aquatic

plants

ErC50 (Desmodesmus subspicatus (green algae)): 370 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Toxicity to fish (Chronic tox- : NOEC (Danio rerio (zebra fish)): 13.5 mg/l

according to GB/T 16483 and GB/T 17519



Oxytetracycline / Diclofenac Formulation

Version Revision Date: SDS Number: Date of last issue: 2025/04/14 7.1 2025/05/20 4156023-00020 Date of first issue: 2019/04/17

icity) Exposure time: 35 d

Method: OECD Test Guideline 210

Remarks: Based on data from similar materials

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 5.6 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Remarks: Based on data from similar materials

Toxicity to microorganisms : EC50: > 1,000 mg/l

Exposure time: 4 h

Remarks: Based on data from similar materials

Persistence and degradability

Components:

2-Pyrrolidone:

Biodegradability : Result: Readily biodegradable.

Remarks: Based on data from similar materials

Sodium hydroxymethanesulphinate:

Biodegradability : Result: Readily biodegradable.

Biodegradation: 77 % Exposure time: 28 d

Method: OECD Test Guideline 301B

Remarks: Based on data from similar materials

Bioaccumulative potential

Components:

2-Pyrrolidone:

Partition coefficient: n- : log Pow: -0.71

octanol/water Method: OECD Test Guideline 107

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Partition coefficient: n- : log Pow: 4.51

octanol/water

Mobility in soil

No data available

Other adverse effects

No data available

according to GB/T 16483 and GB/T 17519



Oxytetracycline / Diclofenac Formulation

Version Revision Date: SDS Number: Date of last issue: 2025/04/14 7.1 2025/05/20 4156023-00020 Date of first issue: 2019/04/17

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(Oxytetracycline)

Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3082

Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.

(Oxytetracycline)

Class : 9 Packing group : III

Labels : Miscellaneous

Packing instruction (cargo

aircraft)

Packing instruction (passen- : 964

ger aircraft)

Environmentally hazardous : yes

IMDG-Code

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

964

(Oxytetracycline)

Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

according to GB/T 16483 and GB/T 17519



Oxytetracycline / Diclofenac Formulation

Version Revision Date: SDS Number: Date of last issue: 2025/04/14 7.1 2025/05/20 4156023-00020 Date of first issue: 2019/04/17

GB 6944/12268

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(Oxytetracycline)

Class : 9
Packing group : III
Labels : 9
Marine pollutant : yes

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

15. REGULATORY INFORMATION

National regulatory information

Law on the Prevention and Control of Occupational Diseases

Regulations on Safety Management of Hazardous Chemicals

Catalogue of Hazardous Chemicals : This product is not listed in the cata-

logue of hazardous chemicals, but it meets the definition of hazardous chemicals and its principles of de-

termination.

Identification of Major Hazard Installations for Hazardous Chemicals (GB : Not listed

18218)

Hazardous Chemicals for Priority Management under : Not listed

SAWS

Catalogue of Specially Controlled Hazardous Chemi: Not listed

cals

List of Explosive Precursors : Not listed

Regulations on Labour Protection in Workplaces where Toxic Substances are Used

Catalogue of Highly Toxic Chemicals : Not listed

Regulation of Environmental Management on the First Import of Chemicals and the Import and Export of Toxic Chemicals

China Severely Restricted Toxic Chemicals for Import : Not listed

and Export

Regulation on the Administration of Precursor Chemicals

according to GB/T 16483 and GB/T 17519



Oxytetracycline / Diclofenac Formulation

Version Revision Date: SDS Number: Date of last issue: 2025/04/14 7.1 2025/05/20 4156023-00020 Date of first issue: 2019/04/17

Catalogue and Classification of Precursor Chemicals : Not listed

Yangtze River Protection Law

This product is prohibited only for bulk transport in inland river.

Regulations of Ozone Depleting Substances Management

List of Controlled Ozone Depleting Substances Import : Not listed

and Export

List of Controlled Ozone Depleting Substances Not listed

Environmental Protection Law

List of Priority Controlled Chemicals Not listed

List of Key Controlled New Pollutants Listed

The components of this product are reported in the following inventories:

AICS not determined

DSL not determined

IECSC not determined

16. OTHER INFORMATION

Revision Date 2025/05/20

Further information

compile the Safety Data

Sheet

Sources of key data used to : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Date format : yyyy/mm/dd

Full text of other abbreviations

ACGIH USA. ACGIH Threshold Limit Values (TLV)

CN OEL Occupational exposure limits for hazardous agents in the

workplace - Chemical hazardous agents.

ACGIH / TWA 8-hour, time-weighted average

CN OEL / PC-TWA Permissible concentration - time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation: DSL - Domestic Substances List (Canada): ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA

according to GB/T 16483 and GB/T 17519



Oxytetracycline / Diclofenac Formulation

Version Revision Date: SDS Number: Date of last issue: 2025/04/14 7.1 2025/05/20 4156023-00020 Date of first issue: 2019/04/17

- International Air Transport Association: IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States): UN - United Nations: UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CN / EN